Inhibrx Biosciences, Inc. INBX Business Segments — Net income (loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Inhibrx Biosciences, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s business segments — net income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s business segments — net income (loss)?
- Inhibrx Biosciences, Inc. (INBX) reported business segments — net income (loss) of -$32.83M in Q4 2025.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s business segments — net income (loss)?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s business segments — net income (loss) has grown at a -23.8% compound annual growth rate (CAGR), from -$241.36M to -$140.06M.
- What does business segments — net income (loss) mean?
- Represents the bottom-line financial performance of the reportable segment after accounting for all revenues and operating expenses. It is the primary indicator of the segment's overall profitability and its contribution to the company's total financial health.